Latest Breaking News On - Next generation acylfulvene - Page 1 : vimarsana.com

The FDA has granted orphan drug designation to LP-284 for use in the treatment of patients with high-grade B-cell lymphoma harboring MYC and BCL2 rearrangements.

United statesLantern pharma incLantern pharmaLp 284High gradeb cell lymphomaBlood cancerPrecision medMyc and bcl2 rearrangementsOrphan drug designationNext generation acylfulvene